CG PHARMACEUTICALS Trademark

Trademark Overview


On Wednesday, February 16, 2022, a trademark application was filed for CG PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the CG PHARMACEUTICALS trademark a serial number of 97270460. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, October 1, 2024. This trademark is owned by CG Pharmaceuticals, Inc. The CG PHARMACEUTICALS trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:

biopharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of chronic diseases, namely, dementia, Alzheimer's disease, arthritis, rheumatoid arthritis, fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, kidney disease, inflammatory bowel disease, gastrointestinal disease, infectious diseases, neurodegenerative diseases, immunological disorders, and inflammatory diseases; biologic preparations for the treatment of cancer; biologic preparations for the treatment of chronic diseases, namely, dementia, Alzheimer's disease, arthritis, rheumatoid arthritis, fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, kidney disease, inflammatory bowel disease, gastrointestinal disease, infectious diseases, neurodegenerative diseases, immunological disorders, and inflammatory diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of chronic diseases, namely, dementia, Alzheime...

Providing health and medical information about medical disorders and their diagnosis, prevention and treatment; information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatments, including pharmaceutical advice, medical and pharmaceutical consultation, medical advisory services, and providing medical information, consultancy and advisory services; information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatments, including pharmaceutical advice, medical and pharmaceutical consultation, medical advisory services, and providing medical information, consultancy and advisory services provided on-line over a computer network and the Internet; Providing information regarding medical conditions; medical information services; providing medical information regarding testing, diagnosis, and treatment of diseases; providing medical information to patients regarding disease management and medication
cg pharmaceuticals

General Information


Serial Number97270460
Word MarkCG PHARMACEUTICALS
Filing DateWednesday, February 16, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, October 1, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, August 8, 2023

Trademark Statements


Description of MarkThe mark consists of the term CG PHARMACEUTICALS in a stylized format.
Goods and Servicesbiopharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of chronic diseases, namely, dementia, Alzheimer's disease, arthritis, rheumatoid arthritis, fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, kidney disease, inflammatory bowel disease, gastrointestinal disease, infectious diseases, neurodegenerative diseases, immunological disorders, and inflammatory diseases; biologic preparations for the treatment of cancer; biologic preparations for the treatment of chronic diseases, namely, dementia, Alzheimer's disease, arthritis, rheumatoid arthritis, fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, kidney disease, inflammatory bowel disease, gastrointestinal disease, infectious diseases, neurodegenerative diseases, immunological disorders, and inflammatory diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of chronic diseases, namely, dementia, Alzheimer's disease, arthritis, rheumatoid arthritis, fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, kidney disease, inflammatory bowel disease, gastrointestinal disease, infectious diseases, neurodegenerative diseases, immunological disorders, and inflammatory diseases; pharmaceutical preparations and substances for use in oncology treatment; pharmaceuticals for the treatment of cancer; prescription pharmaceuticals for treatment of diseases and disorders, namely, cancer and chronic diseases
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesProviding health and medical information about medical disorders and their diagnosis, prevention and treatment; information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatments, including pharmaceutical advice, medical and pharmaceutical consultation, medical advisory services, and providing medical information, consultancy and advisory services; information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatments, including pharmaceutical advice, medical and pharmaceutical consultation, medical advisory services, and providing medical information, consultancy and advisory services provided on-line over a computer network and the Internet; Providing information regarding medical conditions; medical information services; providing medical information regarding testing, diagnosis, and treatment of diseases; providing medical information to patients regarding disease management and medication
NOT AVAILABLE"PHARMACEUTICALS"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 22, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, February 22, 2022
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCG Pharmaceuticals, Inc
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressOrinda, CA 94563

Party NameCG Pharmaceuticals, Inc
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressOrinda, CA 94563

Trademark Events


Event DateEvent Description
Wednesday, November 30, 2022ASSIGNED TO EXAMINER
Saturday, February 19, 2022NEW APPLICATION ENTERED
Tuesday, February 22, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 1, 2022NON-FINAL ACTION WRITTEN
Thursday, December 1, 2022NON-FINAL ACTION E-MAILED
Thursday, December 1, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 1, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, June 1, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 2, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, July 2, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 19, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 8, 2023PUBLISHED FOR OPPOSITION
Tuesday, August 8, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 3, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 2, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, April 2, 2024SOU EXTENSION 1 FILED
Tuesday, April 2, 2024SOU EXTENSION 1 GRANTED
Tuesday, October 1, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, October 1, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 1, 2024SOU EXTENSION 2 FILED
Tuesday, October 1, 2024SOU EXTENSION 2 GRANTED
Wednesday, April 3, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED